Results 71 to 80 of about 199,785 (356)

Challenges to the development of antigen-specific breast cancer vaccines [PDF]

, 2001
Continued progress in the development of antigen-specific breast cancer vaccines depends on the identification of appropriate target antigens, the establishment of effective immunization strategies, and the ability to circumvent immune escape mechanisms.
B Thurner, BJ Van den Eynde, D Jäger, DH Kaplan, Dirk Jäger, DR Leach, E Jäger, E Jäger, FO Nestle, GP Murphy, IB Runnebaum, JJ Mule, JW Hodge, K Chikamatsu, M Marchand, MA Morse, Matthew J Scanlan, MJ Scanlan, ML Disis, ML Disis, NP Restifo, P van der Bruggen, PA Lodge, RF Wang, S Morel, S Wojtowicz-Praga, T Soussi, U Sahin, U Sahin, Y Kawakami, Y Paterson, YT Chen, YT Chen   +32 more
core   +2 more sources

Translating mRNA vaccines [PDF]

Science-Business eXchange, 2012
CureVac and the Friedrich Loeffler Institute have in vivo evidence that an mRNA-based vaccine can prevent influenza A infection. The results provide proof of concept for the company's vaccine platform in infectious disease and Sanofi has options to the technology.
openaire   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine

Clinical & Translational Immunology, 2022
Objective Despite the high vaccine efficacy of mRNA COVID‐19 vaccines, there are individuals who developed excessive reactogenic and/or allergic responses after the first mRNA dose and were considered ineligible for further mRNA doses.
Yun Shan Goh, Siew‐Wai Fong, Angeline Rouers, Zi Wei Chang, Matthew Zirui Tay, Jean‐Marc Chavatte, Nicole Ziyi Zhuo, Pei Xiang Hor, Chiew Yee Loh, Yuling Huang, Joel Xu En Wong, Yong Jie Tan, Daniel Rui Xiang Lim, Bei Wang, Eve Zi Xian Ngoh, Siti Nazihah Mohd Salleh, Raphael Tze Chuen Lee, Surinder Pada, Louisa Jin Sun, Desmond Luan Seng Ong, Jyoti Somani, Eng Sing Lee, NCID Study Group, COVID‐19 Study Group, Sebastian Maurer‐Stroh, Cheng‐I Wang, Yee‐Sin Leo, Raymond TP Lin, Ee Chee Ren, David C Lye, Barnaby Edward Young, Poh Lian Lim, Lisa FP Ng, Laurent Renia   +33 more
doaj   +1 more source

The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review

Frontiers in Immunology, 2022
Both infectious viral diseases and cancer have historically been some of the most common causes of death worldwide. The COVID-19 pandemic is a decidedly relevant example of the former. Despite progress having been made over past decades, new and improved
Reese Jalal Ladak, Reese Jalal Ladak, Alexander J. He, Yu-Hsun Huang, Yu Ding   +4 more
doaj   +1 more source

Recent advances in malaria genomics and epigenomics [PDF]

, 2016
Malaria continues to impose a significant disease burden on low- and middle-income countries in the tropics. However, revolutionary progress over the last 3 years in nucleic acid sequencing, reverse genetics, and post-genome analyses has generated step ...
Kirchner, Sebastian, Power, B. Joanne, Waters, Andrew P.   +2 more
core   +1 more source

mRNA vaccines: Past, present, future

Asian Journal of Pharmaceutical Sciences, 2022
mRNA vaccines have emerged as promising alternative platforms to conventional vaccines. Their ease of production, low cost, safety profile and high potency render them ideal candidates for prevention and treatment of infectious diseases, especially in the midst of pandemics.
Mia Karam, Georges Daoud
openaire   +3 more sources

COVID‐19 Vaccination is not Associated with the Development of Idiopathic Inflammatory Myositis in U.S. Veterans

Arthritis Care &Research, Accepted Article.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US Veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández, Naomi Schlesinger, Jorge Rojas, Jessica A. Walsh, Tawnie J Braaten, Gary A Kunkel, Makoto Jones, Brian C Sauer, Julio Facelli, Grant W. Cannon, Dorota Lebiedz‐Odrobina   +10 more
wiley   +1 more source

Engaging the Immune Response to Normalize the Tumor Microenvironment [PDF]

, 2013
Solid tumors exist as heterogeneous populations comprised not only of malignant cells, but various other cell types, including cells that make up the vasculature, that can strongly influence tumorgenicity.
Sabins, Nina, Storkus, Walter
core  

Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis. [PDF]

, 2017
Tuberculosis (TB) is characterized by extensive pulmonary matrix breakdown. Interleukin-17 (IL-17) is key in host defence in TB but its role in TB-driven tissue damage is unknown.
Aggarwal, Aguilo, Al Shammari, Aujla, Belton, Berg, Bermudez, Brinckerhoff, Chang, Cortez, Dheda, Dhiman, Domingo-Gonzalez, Elkington, Elkington, Elkington, Elkington, Elkington, Elkington, Fossiez, Freches, Fu, Gideon, Gopal, Hamburg, Hamburg, Happel, Hrabec, Huang, Jovanovic, Kubler, Leber, Matthews, Mayer-Barber, McAleer, McAllister, Miossec, Molet, Nuttall, O'Kane, O'Kane, Okamoto Yoshida, Ong, Oriss, Price, Qiao, Qiu, Rivas-Santiago, Ruddy, Sauty, Scriba, Singh, Singh, Sonnenberg, Torrado, Trajkovic, Treadwell, Volkman, Wang, Wickremasinghe, Wickremasinghe, Wong, Wozniak, Wu, Xu, Zijlstra   +65 more
core   +1 more source